|
Extracellular vesicles as biomarkers of disease
(1) We have established workflows for (i) collection and storage of blood plasma and urine that is compatible with EV research, (ii) isolation of EVs from blood plasma and urine and (iii) characterization of EV size/concentration, RNA, DNA and protein content. We are applying them in several ongoing collaborative biomarker studies with clinical partners on diverse diseases like HIV-1 infection, kidney allograft rejection, diverse cancers.
HOLCAR et al., Scientific reports. 2020 (PubMed)
SEDEJ et al., Journal of extracellular vesicles. 2022 (PubMed)
SEDEJ et al., Clinical nephrology. 2021 (PubMed)
BADOVINAC et al., Journal of personalized medicine. 2021 (PubMed)
BADOVINAC et al., Cancers. 2023 (PubMed)
HOLCAR et al., Frontiers in pharmacology. 2021 (PubMed)
GORIČAR et al., Frontiers in pharmacology. 2021 (PubMed)
HLADNIK et al., Medicinski razgledi. 2022 (Link)
FERDIN et al., Medicinski razgledi. 2016 (Link)
(2) We are also directly involved in ISEV society efforts in promoting Rigor and Standardization in EV research by co-authoring guidelines, reports and recommendations.
LUCIEN et al., Journal of Extracellular Vesicles. 2023 (PubMed)
ERDBRÜGGER et al., Journal of Extracellular Vesicles. 2021 (PubMed)
WELSH et al., Journal of Extracellular Vesicles. 2020 (PubMed)
CLAYTON et al., Journal of Extracellular Vesicles. 2019 (PubMed)
THÉRY et al., Journal of Extracellular Vesicles. 2018 (PubMed)
CLAYTON et al., Journal of Extracellular Vesicles. 2018 (PubMed)
|